Quest Diagnostics (DGX) director acquires 70 shares via DRIP
Quest Diagnostics (DGX) reported an insider transaction by a director.
Rhea-AI Filing Summary
Quest Diagnostics (DGX) reported an insider transaction by a director. On 10/21/2025, the director acquired 70 shares of common stock at $189.082 per share, as disclosed on a Form 4.
The filing states the shares were acquired through a dividend reinvestment plan administered by the broker and were eligible for deferred reporting on Form 5 under Rule 16a-6; the reporting person chose to report early here. Following the transaction, the director beneficially owns 18,287 shares, held directly.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 70 | $189.082 | $13K |
Footnotes (1)
- F1. Reflects shares that were acquired pursuant to a dividend reinvestment plan administered by the reporting person's broker and eligible for deferred reporting on Form 5 under Rule 16a-6. The reporting person has chosen to report such transaction early on this Form 4.
FAQ
What did Quest Diagnostics (DGX) disclose in this Form 4?
A company director acquired 70 shares of common stock on 10/21/2025 at $189.082 per share.
Why is the Form 4 noting Form 5 eligibility?
The transaction was eligible for deferred reporting on Form 5 under Rule 16a-6, but it was reported early on Form 4.
What is the relationship of the reporting person to Quest Diagnostics (DGX)?
The reporting person is a Director of Quest Diagnostics.
Was this Form 4 filed by multiple reporting persons?
No. It was filed by one reporting person.
AI-generated analysis. How Rhea-AI works. Not financial advice.